OBJECTIVES: In the ASPECT-NP trial, ceftolozane/tazobactam was non-inferior to meropenem for treating nosocomial pneumonia; efficacy outcomes by causative pathogen were to be evaluated. METHODS: Mechanically ventilated participants with hospital-acquired/ventilator-associated bacterial pneumonia were randomized to 3 g ceftolozane/tazobactam (2 g ceftolozane/1 g tazobactam) q8h or 1 g meropenem q8h. Lower respiratory tract (LRT) cultures were obtained ≤36 h before first dose; pathogen identification and susceptibility were confirmed at a central laboratory. Prospective secondary per-pathogen endpoints included 28 day all-cause mortality (ACM), and clinical and microbiological response at test of cure (7-14 days after the end of therapy) in the microbiological ITT (mITT) population. RESULTS: The mITT population comprised 511 participants (264 ceftolozane/tazobactam, 247 meropenem). Baseline LRT pathogens included Klebsiella pneumoniae (34.6%), Pseudomonas aeruginosa (25.0%) and Escherichia coli (18.2%). Among baseline Enterobacterales isolates, 171/456 (37.5%) were ESBL positive. For Gram-negative baseline LRT pathogens, susceptibility rates were 87.0% for ceftolozane/tazobactam and 93.3% for meropenem. For Gram-negative pathogens, 28 day ACM [52/259 (20.1%) and 62/240 (25.8%)], clinical cure rates [157/259 (60.6%) and 137/240 (57.1%)] and microbiological eradication rates [189/259 (73.0%) and 163/240 (67.9%)] were comparable with ceftolozane/tazobactam and meropenem, respectively. Per-pathogen microbiological eradication for Enterobacterales [145/195 (74.4%) and 129/185 (69.7%); 95% CI: -4.37 to 13.58], ESBL-producing Enterobacterales [56/84 (66.7%) and 52/73 (71.2%); 95% CI: -18.56 to 9.93] and P. aeruginosa [47/63 (74.6%) and 41/65 (63.1%); 95% CI: -4.51 to 19.38], respectively, were also comparable. CONCLUSIONS: In mechanically ventilated participants with nosocomial pneumonia owing to Gram-negative pathogens, ceftolozane/tazobactam was comparable with meropenem for per-pathogen 28 day ACM and clinical and microbiological response.

General Hospital of Kolin Zizkova 146 Kolin 3 280 00 Czech Republic

Hiroshima University 1 2 3 Kasumi Minami ku Hiroshima 734 8551 Japan

Merck and Co Inc 2000 Galloping Hill Rd Kenilworth NJ 07033 USA

North Estonia Medical Centre Foundation Sütiste tee 19 Tallinn Harjumaa 13419 Estonia

Northwestern University Feinberg School of Medicine 303 East Superior St Simpson Querrey 5th Floor Suite 5 301 Chicago IL 60611 USA

St James's Hospital Trinity College Dublin James Street Dublin 8 Ireland

UMR 1137 IAME Université Paris Diderot F75018 Paris France

Universidade Federal do Paraná Rua XV de Novembro 1299 Centro Curitiba PR 80060 000 Brazil

Universitat de Barcelona IDIBAPS CIBERes Barcelona Spain

Washington University School of Medicine 4523 Clayton Ave Campus Box 8052 St Louis MO 63110 USA

Zobrazit více v PubMed

Kalil  AC, Metersky  ML, Klompas  M  et al.  Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis  2016; 63: e61–111. PubMed PMC

Melsen  WG, Rovers  MM, Groenwold  RHH  et al.  Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis  2013; 13: 665–71. PubMed

Talbot  GH, Das  A, Cush  S  et al.  Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. J Infect Dis  2019; 10: 1536–44. PubMed PMC

Borgatta  B, Gattarello  S, Mazo  CA  et al.  The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs. Eur J Clin Microbiol Infect Dis  2017; 36: 2155–63. PubMed

Tedja  R, Nowacki  A, Fraser  T  et al.  The impact of multidrug resistance on outcomes in ventilator-associated pneumonia. Am J Infect Control  2014; 42: 542–5. PubMed

Timsit  J-F, Pilmis  B, Zahar  J-R. How should we treat hospital-acquired and ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae?  Semin Respir Crit Care Med  2017; 38: 287–300. PubMed

Kaye  KS, Pogue  JM. Infections caused by resistant Gram-negative bacteria: epidemiology and management. Pharmacotherapy  2015; 35: 949–62. PubMed

Carvalhaes  CG, Castanheira  M, Sader  HS  et al.  Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. Diagn Microbiol Infect Dis  2019; 94: 93–102. PubMed

Sader  HS, Castanheira  M, Mendes  RE  et al.  Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17). J Antimicrob Chemother  2018; 73: 3053–9. PubMed

Sader  HS, Castanheira  M, Flamm  RK. Antimicrobial activity of ceftazidime-avibactam against Gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. medical centers, 2011 to 2015. Antimicrob Agents Chemother  2017; 61: e02083-16. PubMed PMC

Rosenthal  VD, Al-Abdely  HM, El-Kholy  AA  et al.  International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: device-associated module. Am J Infect Control  2016; 44: 1495–504. PubMed

Rosenthal  VD, Maki  DG, Mehta  Y  et al.  International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. Am J Infect Control  2014; 42: 942–56. PubMed

Sader  HS, Farrell  DJ, Flamm  RK  et al.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents  2014; 43: 328–34. PubMed

Vincent  J-L, Sakr  Y, Singer  M  et al.  Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA  2020; 323: 1478–87. PubMed PMC

Kumar  A, Ellis  P, Arabi  Y  et al.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest  2009; 136: 1237–48. PubMed

Funk  DJ, Kumar  A. Antimicrobial therapy for life-threatening infections: speed is life. Crit Care Clin  2011; 27: 53–76. PubMed

Kethireddy  S, Bilgili  B, Sees  A  et al.  Culture-negative septic shock compared with culture-positive septic shock: a retrospective cohort study. Crit Care Med  2018; 46: 506–12. PubMed

Kelly  DN, Martin-Loeches  I. Comparing current US and European guidelines for nosocomial pneumonia. Curr Opin Pulm Med  2019; 25: 263–70. PubMed

Torres  A, Niederman  MS, Chastre  J  et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J  2017; 50: 1700582. PubMed

ZERBAXA® (ceftolozane and tazobactam) for injection, for intravenous use . Prescribing Information. Merck Sharp & Dohme Corp, 2020. https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.

Castanheira  M, Duncan  LR, Mendes  RE  et al.  Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. Antimicrob Agents Chemother  2018; 62: e02125-17. PubMed PMC

Shortridge  D, Pfaller  MA, Castanheira  M  et al.  Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. Diagn Microbiol Infect Dis  2018; 92: 158–63. PubMed

Karlowsky  JA, Lob  SH, Young  K  et al.  Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019. BMC Microbiol  2021; 21: 74. PubMed PMC

Karlowsky  JA, Kazmierczak  KM, Young  K  et al.  In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis  2020; 96: 114925. PubMed

Chandorkar  G, Huntington  JA, Gotfried  MH  et al.  Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother  2012; 67: 2463–9. PubMed

Caro  L, Nicolau  DP, De Waele  JJ  et al.  Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3  g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother  2020; 75: 1546–53. PubMed PMC

Kollef  MH, Novacek  M, Kivistik  U  et al.  Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis  2019; 19: 1299–311. PubMed

Xiao  AJ, Miller  BW, Huntington  JA  et al.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol  2016; 56: 56–66. PubMed PMC

Rodvold  KA, Hope  WW, Boyd  SE. Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol  2017; 36: 114–23. PubMed

Puzniak  L, Dillon  R, Palmer  T  et al.  Systematic literature review of real-world evidence of ceftolozane/tazobactam for the treatment of respiratory infections. Infect Dis Ther  2021; 10: 1227–52. PubMed PMC

CLSI . Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically—Eleventh Edition: M07. 2018.

CLSI . Performance Standards for Antimicrobial Susceptibility Testing—Twenty-Eighth Edition: M100. 2018.

Castanheira  M, Johnson  MG, Yu  B  et al.  Molecular characterization of baseline Enterobacterales and Pseudomonas aeruginosa isolates from a phase 3 nosocomial pneumonia (ASPECT-NP) clinical trial. Antimicrob Agents Chemother  2021; 65: e02461-20. PubMed PMC

Johnson  MG, Bruno  C, Castanheira  M  et al.  Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). Int J Antimicrob Agents  2021; 57: 106278. PubMed

Jones  RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis  2010; 51  Suppl 1: S81–7. PubMed

Weiner  LM, Webb  AK, Limbago  B  et al.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol  2016; 37: 1288–301. PubMed PMC

Shortridge  D, Pfaller  MA, Arends  SJR  et al.  Comparison of the in vitro susceptibility of ceftolozane-tazobactam with the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia. Open Forum Infect Dis  2019; 6: ofz240. PubMed PMC

Shortridge  D, Pfaller  MA, Streit  JM  et al.  Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme. J Glob Antimicrob Resist  2020; 21: 60–4. PubMed

Mikamo  H, Monden  K, Miyasaka  Y  et al.  The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections. J Infect Chemother  2019; 25: 111–6. PubMed

Solomkin  J, Hershberger  E, Miller  B  et al.  Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis  2015; 60: 1462–71. PubMed PMC

Wagenlehner  FM, Umeh  O, Steenbergen  J  et al.  Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet  2015; 385: 1949–56. PubMed

Pogue  JM, Heil  EL. Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world. Expert Opin Pharmacother  2019; 20: 2053–57. PubMed

Harris  PNA, Tambyah  PA, Lye  DC  et al.  Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA  2018; 320: 984–94. PubMed PMC